21 results match your criteria International Journal of Drug Discovery [Journal]

  • Page 1 of 1

Addressing challenges in the diagnosis and treatment of rare genetic diseases.

Nat Rev Drug Discov 2018 Mar 15;17(3):151-152. Epub 2017 Dec 15.

International Rare Diseases Research Consortium.

The past 5 years have seen an unprecedented rate of discovery of genes that cause rare diseases and with it a commensurate increase in the number of diagnosable but nevertheless untreatable disorders. Here, we discuss the increasing opportunity for diagnosis and therapy of rare diseases and how to tackle the associated challenges. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrd.2017.246DOI Listing
March 2018
8 Reads

Legacy data sharing to improve drug safety assessment: the eTOX project.

Nat Rev Drug Discov 2017 Dec 13;16(12):811-812. Epub 2017 Oct 13.

Lead Molecular Design S.L., 08172 Sant Cugat del Vallès, Spain.

The sharing of legacy preclinical safety data among pharmaceutical companies and its integration with other information sources offers unprecedented opportunities to improve the early assessment of drug safety. Here, we discuss the experience of the eTOX project, which was established through the Innovative Medicines Initiative to explore this possibility. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrd.2017.177DOI Listing
December 2017
53 Reads

Regulatory watch: Structural and procedural characteristics of international regulatory authorities.

Nat Rev Drug Discov 2017 09 11;16(9):594. Epub 2017 Aug 11.

Novo Nordisk Healthcare AG, Thurgauerstrasse 36, CH-8050 Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrd.2017.135DOI Listing
September 2017
64 Reads

Targeting iron metabolism in drug discovery and delivery.

Nat Rev Drug Discov 2017 Jun 3;16(6):400-423. Epub 2017 Feb 3.

Children's Hospital of Philadelphia, Abramson Research Center, Philadelphia, Pennsylvania 19104, USA.

Iron fulfils a central role in many essential biochemical processes in human physiology; thus, proper processing of iron is crucial. Although iron metabolism is subject to relatively strict physiological control, numerous disorders, such as cancer and neurodegenerative diseases, have recently been linked to deregulated iron homeostasis. Consequently, iron metabolism constitutes a promising and largely unexploited therapeutic target for the development of new pharmacological treatments for these diseases. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/doifinder/10.1038/nrd.2016.248
Publisher Site
http://dx.doi.org/10.1038/nrd.2016.248DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455971PMC
June 2017
30 Reads

Strategies for delivering value from digital technology transformation.

Authors:
Eric D Perakslis

Nat Rev Drug Discov 2017 Feb 13;16(2):71-72. Epub 2017 Jan 13.

Takeda R&D Data Science Institute, Takeda Pharmaceuticals International, 35 Landsdowne Street, Cambridge, Massachusetts 02139, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrd.2016.265DOI Listing
February 2017
4 Reads

Use of surrogate end points in healthcare policy: a proposal for adoption of a validation framework.

Nat Rev Drug Discov 2016 Jul 3;15(7):516. Epub 2016 Jun 3.

Evidence Synthesis and Modelling for Health Improvement, Institute of Health Research, University of Exeter Medical School, Exeter EX1 2LU, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrd.2016.81DOI Listing
July 2016
7 Reads

Putting translational science on to a global stage.

Nat Rev Drug Discov 2016 04;15(4):217-8

EATRIS ERIC, European Infrastructure for Translational Medicine, Amsterdam 1081 HZ, Netherlands.

Global collaboration in translational science promises to accelerate the discovery, development and dissemination of new medical interventions. Here, we introduce a new international collaboration of translational science organizations and highlight our initial strategy to reduce or remove bottlenecks in translation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrd.2016.33DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378162PMC
April 2016
8 Reads

The European Medicines Agency's strategies to meet the challenges of Alzheimer disease.

Nat Rev Drug Discov 2015 Apr;14(4):221-2

Bundesinstitut für Arzneimittel und Medizinprodukte, Kurt-Georg-Kiesinger-Allee 3 53175 Bonn, Germany.

Regulatory agencies have a key role in facilitating the development of new drugs for Alzheimer disease, particularly given the challenges associated with early intervention. Here, we highlight the strategies of the European Medicines Agency to help address such challenges. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrd4585DOI Listing
April 2015
4 Reads

The international serious adverse events consortium.

Nat Rev Drug Discov 2014 Nov;13(11):795-6

iSAEC Scientific Management Committee and at GlaxoSmithKline, Research Triangle Park, North Carolina 27709-3398, USA.

The International Serious Adverse Events Consortium is generating novel insights into the genetics and biology of drug-induced serious adverse events, and thereby improving pharmaceutical product development and decision-making. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrd4441DOI Listing
November 2014
12 Reads

Applying insights from biofilm biology to drug development - can a new approach be developed?

Nat Rev Drug Discov 2013 Oct;12(10):791-808

1] Department of International Health, Immunology and Microbiology, Costerton Biofilm Centre Faculty of Health Sciences, University of Copenhagen, 2200 Copenhagen N, Denmark. [2] Department of Clinical Microbiology, Rigshospitalet, 2100 Copenhagen Ø, Denmark.

Most of the research on bacterial pathogenesis has focused on acute infections, but much less is known about the pathogenesis of infections caused by bacteria that grow as aggregates in biofilms. These infections tend to be chronic as they resist innate and adaptive immune defence mechanisms as well as antibiotics, and the treatment of biofilm infections presents a considerable unmet clinical need. To date, there are no drugs that specifically target bacteria in biofilms; however, several approaches are in early-stage development. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/nrd/journal/v12/n10/pdf/nrd4000.pdf?WT
Web Search
http://dx.doi.org/10.1038/nrd4000DOI Listing
October 2013
5 Reads

Pharmacological approaches to restore mitochondrial function.

Nat Rev Drug Discov 2013 Jun 13;12(6):465-83. Epub 2013 May 13.

Laboratory of Integrative and Systems Physiology, École Polytechnique Fédérale de Lausanne, CH-1015 Lausanne, Switzerland.

Mitochondrial dysfunction is not only a hallmark of rare inherited mitochondrial disorders but also implicated in age-related diseases, including those that affect the metabolic and nervous system, such as type 2 diabetes and Parkinson's disease. Numerous pathways maintain and/or restore proper mitochondrial function, including mitochondrial biogenesis, mitochondrial dynamics, mitophagy and the mitochondrial unfolded protein response. New and powerful phenotypic assays in cell-based models as well as multicellular organisms have been developed to explore these different aspects of mitochondrial function. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrd4023DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3896945PMC
June 2013
18 Reads

Membrane transporters in drug development.

Nat Rev Drug Discov 2010 Mar;9(3):215-36

Membrane transporters can be major determinants of the pharmacokinetic, safety and efficacy profiles of drugs. This presents several key questions for drug development, including which transporters are clinically important in drug absorption and disposition, and which in vitro methods are suitable for studying drug interactions with these transporters. In addition, what criteria should trigger follow-up clinical studies, and which clinical studies should be conducted if needed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrd3028DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3326076PMC
March 2010
28 Reads

HIV drug development: the next 25 years.

Authors:
Charles Flexner

Nat Rev Drug Discov 2007 Dec;6(12):959-66

Johns Hopkins University, Divisions of Clinical Pharmacology and Infectious Diseases, Departments of Medicine, Pharmacology and Molecular Sciences, and International Health, Baltimore, Maryland 21287-5554, USA.

The development of drugs for HIV infection began soon after the virus was discovered 25 years ago. Since then, progress has been substantial, but numerous uncertainties persist about the best way to manage this disease. Here we review the current treatment options, consider novel mechanisms that can be exploited for existing drug targets, and explore the potential of novel targets. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nrd2336
Publisher Site
http://dx.doi.org/10.1038/nrd2336DOI Listing
December 2007
7 Reads

Issues in the design and implementation of vaccine trials in less developed countries.

Nat Rev Drug Discov 2006 Nov;5(11):932-40

International Vaccine Institute, Seoul, Korea.

There is a growing need for vaccine trials in developing countries. This need arises from the fact that some vaccines do not perform as well in developing as in industrialized country populations and because some newly developed candidates target diseases found only in less-developed countries. Here we discuss several key issues in the design and implementation of vaccine trials in less-developed countries. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrd2159DOI Listing
November 2006
2 Reads

PI3Kgamma inhibition: towards an 'aspirin of the 21st century'?

Nat Rev Drug Discov 2006 Nov 13;5(11):903-18. Epub 2006 Oct 13.

Serono Pharmaceutical Research Institute, Serono International S.A., 14 Chemin des Aulx, 1228 Plan-les-Ouates, Geneva, Switzerland.

Class IB phosphatidylinositol 3-kinase p110gamma (PI3Kgamma) has gained increasing attention as a promising drug target for the treatment of inflammatory disease. Extensive target-validation data are available, which are derived from studies using both pharmacological and genetic tools. More recent findings have uncovered further therapeutic applications for PI3Kgamma inhibitors, opening up potentially huge opportunities for these drugs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrd2145DOI Listing
November 2006
3 Reads

Bortezomib.

Nat Rev Drug Discov 2003 Aug;2(8):611-2

Decision Resources International, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrd1159DOI Listing
August 2003
6 Reads

Microbicides: a new approach to preventing HIV and other sexually transmitted infections.

Authors:
Alan Stone

Nat Rev Drug Discov 2002 Dec;1(12):977-85

International Family Health, Cityside House, 40 Adler Street, London E1 1EE, UK.

Many chemical agents can block human immunodeficiency virus (HIV) infection in the laboratory. Scientists are investigating which of these, used intravaginally by women, will safely prevent the sexual transmission of HIV in humans. Several such products - microbicides - will soon be tested in populations at high risk for HIV, and others are waiting in the wings. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrd959DOI Listing
December 2002
3 Reads

The role of pharmacology in drug discovery.

Nat Rev Drug Discov 2002 03;1(3):237-8

Department of Physiology and Pharmacology, Karolinska Institutet, S-17177 Stockholm, Sweden.

The International Union of Pharmacology (IUPHAR) enthusiastically welcomes the decision by the Nature Publishing Group to launch its new journal, Nature Reviews Drug Discovery. The title of the new journal poses interesting questions for pharmacologists. Why 'Drug Discovery'? Would we have preferred 'Pharmacology'? And do these distinctions even matter, as aren't all pharmacologists involved somehow in drug discovery? Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nrd749
Publisher Site
http://dx.doi.org/10.1038/nrd749DOI Listing
March 2002
4 Reads

Pharmaceutical consultancy: a view to a skill.

Nat Rev Drug Discov 2002 Apr;1(4):323

Wood Mackenzie, Tower 42, International Finance Centre, 25 Old Broad Street, London EC2N 1HN, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrd782DOI Listing
April 2002
2 Reads
  • Page 1 of 1